

## Literatura

- Ahlqvist E, et al. Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables. *Lancet Diabetes Endocrinol.* 2018;6:361-369.
- Ahrén B. DPP-4 inhibitors. *Best Pract Res Clin Endocrinol Metab.* 2007;21:517-33.
- Anfossi G, et al. The cardiovascular effects of metformin: further reasons to consider an old drug as a cornerstone in the therapy of type 2 diabetes mellitus. *Curr Vasc Pharmacol.* 2010;8:327-37.
- Apovian C, et al. Effects of lorcaserin on fat and lean mass loss in obese and overweight patients without and with type 2 diabetes mellitus: the BLOSSOM and BLOOM-DM studies. *Diabetes Obes Metab.* 2016;18:945-8.
- Aronson JK. Meyler's side effects of endocrine and metabolic drugs. Elsevier 2009;367- 381.
- Aspry KE, et al. Medical nutrition education, training, and competencies to advance guideline-based diet counseling by physicians: a science advisory from the American Heart Association. *Circulation.* 2018;137:e821-e841.
- Astrup A, et al. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. *Lancet* 2009;374: 1606-16.
- Baetta R, Corsini A. Pharmacology of dipeptidyl peptidase-4 inhibitors: similarities and differences. *Drugs.* 2011;71:1441-67.
- Baggio LL. Biology of incretins: GLP-1 and GIP. *Gastroenterology* 2007;132:2131- 2157.
- Bailey CJ, et al. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. *Lancet.* 2010;375:2223-33.
- Bailey CJ, et al. Metformin and the intestine. *Diabetologia.* 2008;51: 1552-1553.
- Ben Sahra I, et al. Metformin in cancer therapy: a new perspective for an old antidiabetic drug? *Mol Cancer Ther.* 2010;9:1092-9.
- Bleau C, Karelis AD, St-Pierre DH, Lamontagne L. Crosstalk between intestinal microbiota, adipose tissue and skeletal muscle as an early event in systemic low grade inflammation and the development of obesity and diabetes. *Diabetes Metab Res Rev.* 2014 Oct 28.

- Brackett CC. Clarifying metformin's role and risks in liver dysfunction. *J Am Pharm Assoc.* 2010;50:407-10.
- Campbell JE, Drucker DJ. Pharmacology, physiology, and mechanisms of incretin hormone action. *Cell Metabolism.* 2013;17:819-837.
- Currie CJ, Poole CD, Gale EA. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. *Diabetologia.* 2009;52(9):1766-77.
- De Fronzo RA. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. *Diabetes.* 2009;58:773-795.
- Diamant M, et al. Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. *Lancet.* 2010;375:2234-43.
- Eisen A, et al. The benefit of adding ezetimibe to statin therapy in patients with prior coronary artery bypass graft surgery and acute coronary syndrome in the IMPROVE-IT trial. *Eur Heart J.* 2016 Aug 28. pii: ehw377.
- Feinman RD, et al. Dietary carbohydrate restriction as the first approach in diabetes management: critical review and evidence base. *Nutrition.* 2015;31:1-13.
- Ferrannini E, et al. A phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes. *Diabetes Care.* 2013;36(12):4015-21.
- Ferrannini E, et al. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial. *Diabetes Care.* 2010;33:2217-24.
- Ferrannini E, et al. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. *J Clin Invest.* 2014;124:499-508.
- Fischer M, McMurray J. *Diabetic cardiology.* Hoboken: Wiley, 2010.
- Fisman EZ, Tenenbaum A (eds.). *Cardiovascular diabetology. Advances in cardiology.* Vol. 45. Basel: Karger, 2008.
- Fonseca V. *Clinical diabetes.* Saunders, NY, 2006.
- Foretz M, et al. Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. *J Clin Invest.* 2010;120:2355-2369.
- Fried M, Doležalová K, et al. *Bariatrická a metabolická chirurgie.* Praha: Mladá fronta, 2011.
- Fried M, Svačina Š, Owen K. *Bariatrická chirurgie a diabetes. Trendy v diabetologii 10.* Ed. Svačina Š. Praha: Galén, 2005.
- Garber AJ, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm 2016: Executive Summary. *Endocr Pract.* 2016;22:84-113.

- Giordano A, et al. White, brown and pink adipocytes: the extraordinary plasticity of the adipose organ. *Eur J Endocrinol*. 2014;170:R159-71.
- Golay A. Metformin and body weight. *Int J Obes*. 2008;32:61-72.
- Gough SC, et al. Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes. *Lancet Diabetes Endocrinol*. 2014;2:885-93.
- Gras V, et al. Effect of metformin on survival rate in experimental sepsis. *Diabetes Metab*. 2006;32(2):147-50.
- Green JB, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. *N Engl J Med*. 2015;373:232-42.
- Guo Y, et al. Assessing the added predictive ability of a metabolic syndrome severity score in predicting incident cardiovascular disease and type 2 diabetes: the Atherosclerosis Risk in Communities Study and Jackson Heart Study. *Diabetol Metab Syndr*. 2018;10:42.
- Hall S, Isaacs D, Clements JN. Pharmacokinetics and clinical implications of semaglutide: a new glucagon-like peptide (GLP)-1 receptor agonist. *Clin Pharmacokinet*. 2018 Jun 19. e-publ.
- Haluzík M, Svačina Š. Gliptiny. *Trendy v diabetologii 12*. Ed. Haluzík M. Praha: Galén, 2008.
- Haluzík M, Svačina Š. *Inkretinová léčba diabetu*. Praha: Mladá fronta, 2011.
- Haluzík M, Svačina Š. *Metabolický syndrom a jaderné receptory PPAR*. Praha: Grada, 2004.
- Hay DL, et al. Amylin: pharmacology, physiology, and clinical potential. *Pharmacol Rev*. 2015;67:564-600.
- Heerspink HJ, et al. Dapagliflozin reduces albuminuria in patients with diabetes and hypertension receiving renin-angiotensin blockers. *Diabetes Obes Metab*. 2016;18:590-7.
- Henry RR, et al. Randomized trial of continuous subcutaneous delivery of exenatide by ITCA 650 versus twice-daily exenatide injections in metformin-treated type 2 diabetes. *Diabetes Care*. 2013;36:2559-65.
- Holman RR, Watkins PJ (eds). *UKPDS: the first 30 years*. Oxford: Wiley-Blackwell, 2008:176 s.
- Inzucchi SE, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. *Diabetes Care*. 2015;38:140-149.
- James WP, et al. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. *N Engl J Med*. 2010;363:905-17.

- Jansen HJ, et al. Start of insulin therapy in patients with type 2 diabetes mellitus promotes the influx of macrophages into subcutaneous adipose tissue. *Diabetologia*. 2013;56:2573-81.
- Jiménez A, Casamitjana R, Flores L, et al. Long-term effects of sleeve gastrectomy and Roux-en-Y gastric bypass surgery on type 2 diabetes mellitus in morbidly obese subjects. *Ann Surg*. 2012;256:1023-9.
- Jung SH, Ha KH, Kim DJ. Visceral fat mass has stronger associations with diabetes and prediabetes than other anthropometric obesity indicators among Korean adults. *Yonsei Med J*. 2016;57:674-80.
- Kahn SE, Haffner SM, Heise MA, et al.; ADOPT Study Group: Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. *N Engl J Med*. 2006;355:2427-43.
- Kaku K, et al. Long-term safety and efficacy of fasiglifam (TAK-875), a G-protein-coupled receptor 40 agonist, as monotherapy and combination therapy in Japanese patients with type 2 diabetes: a 52-week open-label phase III study. *Diabetes Obes Metab*. 2016;18:925-9.
- Kalender A, et al. Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner. *Cell Metab*. 2010;11:390-401.
- Kanazawa I. Usefulness of metformin in diabetes-related bone disease. *Clin Calcium*. 2009;19:1319-25.
- Karen I, a kol. Léčba diabetes mellitus u starších pacientů. Doporučený postup pro praktické lékaře. SVL, 2013.
- Karen I, a kol. Prediabetes. Doporučený postup pro praktické lékaře. SVL, 2013.
- Karen I, Svačina Š (eds). Diabetes mellitus v primární péči. 2. rozšířené vydání. Praha: Axonite, 2014.
- Kim D, et al. Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes. *Diabetes Care*. 2007;30:1487-93.
- Klonoff DC, et al. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. *Curr Med Res Opin*. 2008;24:275-86.
- Komorita Y, et al. Impact of body weight loss from maximum weight on fragility bone fractures in Japanese patients with type 2 diabetes: The Fukuoka Diabetes Registry. *Diabetes Care*. 2018;41:1061-1067.
- Korbonits M (ed.). Obesity and metabolism. Basel: Karger, 2008.
- Kuecker CM, Vivian EM. Patient considerations in type 2 diabetes - role of combination dapagliflozin-metformin XR. *Diabetes Metab Syndr Obes*. 2016;9:25-35.
- Lajka, J. a kol. Výsledky výzkumu obezity v ČR. Projekt VZP Žij zdravě. [www.zijzdrave.cz](http://www.zijzdrave.cz) Praha: STEM/MARK, 2013.
- Landman GW, et al. Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16. *Diabetes Care*. 2010;33:322-6.

- Levri KM, et al. Metformin as treatment for overweight and obese adults: a systematic review. *Ann Fam Med*. 2005;3:457-61.
- Libby G, et al. New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. *Diabetes Care*. 2009;32:1620-5.
- Lily M, Godwin M. Treating prediabetes with metformin. *Can Fam Physicians*. 2009;55:363-369.
- Lingvay I, et al. Effect of insulin glargine up-titration vs insulin degludec/liraglutide on glycated hemoglobin levels in patients with uncontrolled type 2 diabetes: The DUAL V Randomized Clinical Trial. *JAMA*. 2016;315:898-907.
- Logue J, Walker JJ, Colhoun, et al.; Scottish Diabetes Research Network Epidemiology Group. Do men develop type 2 diabetes at lower body mass indices than women? *Diabetologia*. 2011;54:3003-6.
- Macconell L, et al. Exenatide once weekly: sustained improvement in glycemic control and cardiometabolic measures through 3 years. *Diabetes Metab Syndr Obes*. 2013;6:31-41.
- Marso SP, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. *N Engl J Med*. 2016;375:311-22.
- Marso SP, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. *N Engl J Med*. 2016 Sep 15.
- Matsumoto K, et al. Metformin attenuates progression of carotid arterial wall thickness in patients with type 2 diabetes. *Diabetes Res Clin Pract*. 2004;64:225-8.
- McAuley PA, et al. The obesity paradox and cardiorespiratory fitness. *J Obes*. 2012;2012:951-58.
- Morgan CL, et al. Impact of treatment with pioglitazone on stroke outcomes: A real-world database analysis. *Diabetes Obes Metab*. 2018 May 7. doi: 10.1111/dom.13344. [Epub ahead of print].
- Nathan DM, et al. Impaired fasting glucose and impaired glucose tolerance: implications for care. *Diabetes Care*. 2007;30:753-9.
- Nathan DM, et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and European Association for the Study of Diabetes. *Diabetes Care*. 2009;32:193-203.
- National Institute of Health - ARIC study. [www.nhlbi.nih.gov/science/atherosclerosis-risk-communities-aric-study](http://www.nhlbi.nih.gov/science/atherosclerosis-risk-communities-aric-study)
- Nauck M. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. *Diabetologia*. 1986;29:46-52.
- Nissen SE, et al. Effect of naltrexone-bupropion on major adverse cardiovascular events in overweight and obese patients with cardiovascular risk factors: a randomized clinical trial. *JAMA*. 2016;315:990-1004.

- ORIGIN Trial Investigators Gerstein HC, et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. *N Engl J Med.* 2012;367:319–28.
- Pajvani UB, Accili D. The new biology of diabetes. *Diabetologia.* 2015;58:2459–68.
- Palmer SC, et al. Comparison of clinical outcomes and adverse events associated with glucose-lowering drugs in patients with type 2 diabetes: a meta-analysis. *JAMA.* 2016;316:313–24.
- Pearce EL. Enhancing CD8 T-cell memory by modulating fatty acid metabolism. *Nature.* 2009;460:103–7.
- Pedersen BK. Muscle as a secretory organ. *Compr Physiol.* 2013;3:1337–62.
- Pfeffer MA, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. *N Engl J Med.* 2015;373:2247–57.
- Polidori D, et al. Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: results of a randomized, placebo-controlled study. *Diabetes Care.* 2013;36:2154–2161.
- Raaschou-Nielsen O, et al. Long-term exposure to traffic-related air pollution and diabetes-associated mortality: a cohort study. *Diabetologia.* 2013;56:36–46.
- Reaven GM. Role of insulin resistance in human disease (syndrome X): an expanded definition. *Ann Rev Med.* 1993;44:121–31.
- Rosenstock J, et al. Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes. *Diabetes Care.* 2012;35:1232–8.
- Rosenstock J, et al. Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia. *Diabetes Obes Metab.* 2013;15:1154–60.
- Salsali A, et al. Cardiovascular safety of empagliflozin in patients with type 2 diabetes: a meta-analysis of data from randomized placebo-controlled trials. *Diabetes Obes Metab.* 2016;18:1034–40.
- Sa-Nguanmoo P. Potential roles of fibroblast growth factor 21 in the brain. *Metab Brain Dis.* 2016;31:239–48.
- Sattar N, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. *Lancet.* 2010;375:735–42.
- Scarpello JH, et al. Metformin therapy and clinical use. *Diab Vasc Res.* 2008;5:157–67.
- Scirica BM, et al. Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial. *Circulation.* 2014;130:1579–88.
- Scott LJ. Exenatide extended-release: a review of its use in type 2 diabetes mellitus. *Drugs.* 2012;72:1679–7.

- Shyangdan DS. Glucagon-like peptide analogues for type 2 diabetes mellitus: systematic review and meta-analysis. *BMC Endocr Disord.* 2010;10:20-30.
- Simopoulos AP, Ordovas, JM (eds). *Nutrigenetics and nutrigenomics.* Basel: Karger, 2004.
- Sinclair AJ, et al. European Diabetes Working Party for Older People 2011. Clinical guidelines for type 2 diabetes mellitus. Executive summary. Diabetes Working Party for Older People. *Diabetes Metab.* 2011;37 Suppl 3:S27-38.
- Sjostrom CD, et al. Reduction in incidence of diabetes, hypertension and lipid disturbances after intentional weight loss induced by bariatric surgery: the SOS Intervention Study. *Obes Res.* 1999;5:477-84.
- Slapničková M. S červy proti obezitě? *Vesmír.* 2012;91:666-72.
- Smith L, et al. The new face of hyperlipidemia management: proprotein convertase subtilisin/kexin inhibitors (PCSK-9) and their emergent role as an alternative to statin therapy. *J Pharm Pharm Sci.* 2016;19:137-46.
- Sonesson C, Johansson PA, Johnsson E, et al. Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a meta-analysis. *Cardiovasc Diabetol.* 2016;15:37.
- Srivastava G, Apovian C. Future pharmacotherapy for obesity: new anti-obesity drugs on the horizon. *Curr Obes Rep.* 2018;7:147-161.
- Stránská Z, Svačina Š. Myokiny – hormony svalové tkáně. *Vnitr Lek.* 2015;61:365-8.
- Svačina Š. *Antidiabetika – historie, současnost a budoucnost.* Praha: Axonite, 2016.
- Svačina Š. Diabetická osteopatie: onemocnění – kdysi sporné a pravděpodobně významné. *Vnitr Lek* 2010;56:1225-7.
- Svačina Š. Exenatid s prodlouženým uvolňováním v léčbě diabetu – možnost podávání 1× týdně. *Farmakoterapie.* 2014;8:1-5.
- Svačina Š. Metformin – antidiabetikum první volby. *Vnitr Lek.* 2010;56:1225-7.
- Svačina Š. Mikrobiální flóra trávicího traktu a diabetes. *Vnitr Lek.* 2015;4:361-4.
- Svačina Š. Minulost a současnost centrálně působících antiobezitik. *Medicína Promoci.* 2016;17:265-268.
- Svačina Š. Mysimba – nové centrálně působící antiobezitikum. *Practicus.* 2016;15:33-36.
- Svačina Š. Nádory ledvin, močového měchýře a prostaty u obezity a diabetu. *Vnitr Lek.* 2008;54:464-7.
- Svačina Š. Naltrexon/bupropion. *Remedia.* 2017;27:127-131.
- Svačina Š. Nový pohled na antidiabetika vzhledem ke klinickému účinku a k tzv. de Fronzovu oktetu. *Med Promoci.* 2016;172:1-4.

- Svačina Š. Nutrigenetika a nutrigenomika. Čas Lék Čes. 2007;11.
- Svačina Š. Obezitologie a teorie metabolického syndromu. Praha: Triton, 2013.
- Svačina Š. Potenciální nová antidiabetika pro příští desetiletí. Vnitr Lek. 2009;55:429-433.
- Svačina Š. Prevence diabetu a jeho komplikací. Praha: Triton, 2008.
- Svačina Š. Proč a jak působí inzulinové přípravky na hmotnost. Vnitr Lek. 2014;60:448-453.
- Svačina Š. Saxagliptin v léčbě diabetes mellitus. Farmakoterapie. 2010;4:458-460.
- Svačina Š, a kol. Klinická dietologie. Praha: Grada, 2008.
- Svačina Š, ed. Poruchy metabolismu a výživy. Praha: Galén, 2010.
- Škrha J, a kol. Diabetologie. Praha: Galén, 2008.
- Šmahelová A. Akutní komplikace diabetu. Praha: Triton, 2006.
- Šmahelová A. Gliptiny - nová skupina léčiv v diabetologii. Farmakoterapie. 2008;3:347-350.
- Šmahelová A. Metformin. Trendy v diabetologii 12. Ed. Haluzík M. Praha: Galén, 2008.
- Šmahelová A. Pioglitazon - využití v léčbě diabetika 2. typu. Kapitoly z kardiologie 2013;4:122-125.
- Šmahelová A, Lášticová M. Diabetologie pro farmaceuty. Praha: Mladá fronta, 2011.
- Štulc T, Sedo A. Inhibition of multifunctional dipeptidyl peptidase-IV: Is there a risk of oncological and immunological adverse effects? Diabetes Res Clin Pract. 2010;88:125-31.
- Tang T, et al. Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Cochrane Database Syst Rev. 2010;(1):CD003053.
- Thompson AM, Trujillo JM. Advances in the treatment of type 2 diabetes: impact of dulaglutide. Diabetes Metab Syndr Obes. 2016;9:125-36.
- Tomlinson B, et al. Effects of glucose-lowering drugs on cardiovascular outcomes in patients with type 2 diabetes. Expert Opin Drug Metab Toxicol. 2016;1-5.
- Tomlinson B, et al. Investigational glucagon-like peptide-1 agonists for the treatment of obesity. Expert Opin Investig Drugs. 2016;25:1167-79.
- Torgerson JS, et al. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care. 2004;27:155-6.
- Toth PP. Linagliptin: a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus. Postgrad Med. 2011;123:46-53.



- Tsai SP, et al. The effect of pre-disease risk factors within within metabolic syndrome. *Diab Res Clin Pract.* 2008;82:48-56.
- UKPDS Group: Effect of intensive blood-glucose control with metformin on complications in overweight with type 2 diabetes (UKPDS 34). *Lancet.* 1998;352:85.
- Ussar S, et al. Receptor antibodies as novel therapeutics for diabetes. *Sci Transl Med.* 2011;3:113-47.
- Wadden TA, et al. Randomized trial of lifestyle modification and pharmacotherapy for obesity. *N Engl J Med.* 2005;353:2111-20.
- Wensveen FM, et al. The "Big Bang" in obese fat: Events initiating obesity-induced adipose tissue inflammation. *Eur J Immunol.* 2015;45:2446-56.
- Wiernsperger NF. Review: 50 years later: is metformin vascular drug with antidiabetic properties? *Brit J Diabetes Vasc Dis.* 2007;7:204-210.
- Wilding JP, et al. A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment. *Diabetes Care.* 2009;32:1656-62.
- Wilding JP, et al. Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years. *Diabetes Obes Metab.* 2014;16:124-36.
- Williams G, Fruhbeck G. Obesity science to practise. Blackwell 2009. 5<sup>th</sup> Annual NHPRS Conference, March 26-29, Toronto, Canada, 2008.
- Wolffenbuttel BH, et al. Relationship of body mass index with efficacy of exenatide twice daily added to insulin glargine in patients with type 2 diabetes. *Diabetes Obes Metab.* 2016;18:829-33.
- Wroge J, Williams NT. Glucagon-like peptide-1 (GLP-1) receptor agonists in cardiac disorders. *Ann Pharmacother.* 2016 Aug 16. E-pub.
- Yabe D, Seino Y. Two incretin hormones GLP-1 and GIP: Comparison of their actions in insulin secretion and  $\beta$  cell preservation. *Progress Biophys Molec Biol.* 2011;107:248-256.
- Zaccardi F, et al. Benefits and harms of once-weekly glucagon-like peptide-1 receptor agonist treatments: a systematic review and network meta-analysis. *Ann Intern Med.* 2016;164:102-13.
- Zinman B, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. *N Engl J Med.* 2015;373:2117-28.
- Zlatohlávek L (ed.). *Dietologie.* Praha: Current Media, 2016.